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In the United States, over 340,000 patients have end-stage
renal disease treated by hemodialysis (HD) and are
dependent on a reliable vascular access. In over 80% of
patients initiating HD, this access is the central venous
catheter (CVC). Although the CVC has many advantages that
make it desirable for dialysis initiation—ease of insertion,
unnecessary maturation time, and availability for immediate
use—it is not without significant disadvantages. The
substantial morbidity and mortality associated with CVC use
has been well documented in the literature.1,2 Initiating and
maintaining HD patients using a CVC is suboptimal from the
perspective of both patient care and associated long-term
costs. Yet, in the United States, the most common HD
access-related event is replacement of any vascular access
type with a CVC.3 Although in recent years greater effort has
be made to reduce CVC use, some patients are unable to
have a functioning arteriovenous fistula or graft created due
to exhaustion of vessels from previous permanent accesses
or limiting comorbidities. In patients dependent on long-
term CVC use, the primary problems are due to malfunction
(‘poor flows’) or infection. Catheter malfunction leads to
inadequate dialysis, the need for costly and inconvenient
intervention, and reduced quality of life. This review will
focus on the etiology, prevention, and management of
CVC-related malfunction.
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DEFINITION OF CATHETER MALFUNCTION
Past definitions of central venous catheter (CVC) malfunc-
tion have included specific criteria pertaining to blood
flow rates (Qb), venous and arterial pressure limits, dialysis
adequacy based on urea kinetics, and other parameters. The
NKF/DOQI guidelines define CVC malfunction as ‘failure to
attain and maintain an extracorporeal blood flow sufficient
to perform hemodialysis (HD) without significantly length-
ening the HD treatment. The Work Group considered
sufficient extracorporeal blood flow to be 300ml/min
(Opinion)’.4 Although it is important to have guideline
definitions for CVC care, the context of the definition should
consider the overall goal of the CVC to provide adequate
dialysis rather than a Qb in isolation. Previous comparisons
of mean Qb of 250, 275, and 300ml/min did not demonstrate
any clinically or statistically significant differences in the Qb’s
ability to predict that a catheter would provide insufficient
flow leading to inadequate dialysis.5 The implications of the
continued unchecked use of the current DOQI definition of
catheter malfunction include escalating numbers of unne-
cessary interventions and their associated costs. There is an
urgent need for the nephrology community to re-evaluate the
definition of catheter malfunction to encompass more than
just the Qb.
ETIOLOGY OF CATHETER MALFUNCTION
Classification
The etiology of CVC malfunction can be categorized
according to positional abnormalities or mechanical ab-
normalities affecting CVC function. The time frame of
occurrence (early vs late following insertion) can be helpful
when considering the etiology of CVC malfunction.
(i) Catheter positional malfunction. Poor initial CVC
positioning/orientation or kinking leading to poor
flows are the most common causes of early failure of
CVC (o7 days following insertion).
The optimal tip position is poorly studied. The K/DOQI
guidelines recommend positioning the tip within the right
atrium. The tip is placed distally in the right atrium while the
patient is lying in a supine position during insertion, as it will
retract proximally by several centimeters when the patient
returns to an upright position. However, the mid right atrium
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is ideally suited for the catheter tip due to its large caliber space,
reducing inadvertent mural wall trauma. Occasionally, the CVC
is inserted into the wrong vessel, such as the azygous vein.
Catheter kinking may occur when the CVC is placed in a
superior neck position that necessitates a sharp bend of the
CVC. Such malpositioning problems can be avoided with
proper placement under fluoroscopy and post-procedure
radiography to evaluate CVC placement before use.
(ii) Catheter mechanical malfunction. The majority of CVC
malfunction occurs in properly oriented and situated
catheters. Mechanical malfunction can be considered
according to its relationship to the CVC as intraluminal,
extraluminal, or intrinsic to the catheter material/
properties and to the timing of occurrence as early
(o7 days) or late (X7 days) following its insertion.
Pathological processes that may begin soon after CVC
insertion, but often do not manifest until later, include
thrombosis (intraluminal), fibrin sheaths (extraluminal),
and infection (a complication of malfunction).6
Early-onset malfunction
Initially, when the vascular endothelium is damaged by the
catheter insertion, the coagulation and inflammatory cas-
cades are propagated, activating leukocytes, releasing myelo-
peroxidase, forming platelet aggregates,7 and resulting in an
intraluminal thrombus at the catheter tip. These physiologi-
cal processes may be iatrogenically enhanced by inadequate
filling of the CVC with anticoagulant in the interdialytic
period (below), leakage of anticoagulant in the CVC lock, or
by inadequate clearance of blood from the CVC at dialysis
discontinuation.
Within 24 h of placement, an extraluminal fibrin sheath
(or ‘sleeve’) commonly develops at the point of catheter
contact with the vessel wall and may eventually completely
enclose the catheter. A full-length sleeve can be established
by 5–7 days.8 The fibrin sleeve results from the initial
inflammatory reaction in response to vessel injury and is
exacerbated by the constant movement and mechanical
irritation of variably bioincompatable catheter material
against its vessel wall. Even the most securely placed CVC
moves because of patient respiration, neck or postural
movements, and turbulent blood flow through the CVC
during the dialysis procedure. The fibrin sleeve is composed
primarily of a collagenous layer produced by smooth muscle
cells and an overlying endothelial cellular layer.9 Endothelial
and red cell elements lie between the collagenous sleeve
and smooth muscle within the vessel wall.9 The sleeve may
create a one-way valve mechanism that limits flow,
characterized by ease of injection of solutions but by
difficultly aspirating. When malfunction occurs in a properly
positioned catheter, over 34 of catheters are associated with
fibrin sleeves (Figures 1–3).
Late-onset malfunction
Although fibrin sleeves may persist and extend for the
duration of the catheter, it differs from the ‘mural thrombus,’
Figure 1 |A two-dimensional echocardiogram demonstrating
a catheter tip in the right atrium and right atrial thrombus.
Figure 2 |A freshly removed catheter with a fibrin sheath
along the length of the extraluminal catheter surface. Picture
courtesy of Dr D Rajan, University of Toronto.
Catheter end
Fibrin sheath
Figure 3 |A fibrin sheath noted during catheter exchange.
Picture courtesy of Dr D Rajan, University of Toronto.
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which emerges from the vessel wall and protrudes into the
lumen, but usually does not completely surround the
catheter.10 This distinction is important due to possible
clinical implications. For example, thrombotic material
adherent to a fibrin sleeve may detach and cause an embolic
event when the catheter is removed, although a mural
thrombus may result in progressive vessel thrombosis and
occlusion even once a catheter is removed. Right atrial
thrombus is a rare but serious consequence of right atrial
endothelial damage from the CVC tip or as an elongation of
an intraluminal thrombus. It can lead to embolic events and
cause complete catheter occlusion (Figure 4).
Finally, central venous stenosis or occlusion is an
extraluminal cause of CVC malfunction that may be
idiopathic, occurring without the presence of previous
foreign bodies such as pacemaker wires; however, it is more
commonly associated with previous CVC use and longer
duration of use.11,12 It tends to occur more frequently on the
left side.13,14 Although the precise pathogenesis is unclear, it
is an important cause of CVC malfunction and may occur in
25–50% of subclavian catheters15,16 and up to 42% of internal
jugular catheters.11,17 Although the recommended treatment
is angioplasty, with or without stent placement,4 its best
prevention is the avoidance of CVC use.
PREVENTION OF CATHETER MALFUNCTION
In an attempt to prevent CVC malfunction, interdialytic CVC
instillation with anticoagulant solutions ‘catheter locks’ have
been employed. Although heparin has been the most
commonly used locking solution,18 recent alternatives,
including citrate and tissue plasminogen activator (TPA),
and oral anticoagulants/antiplatelet agents, such as warfarin,
aspirin, and ticlodipine, have been investigated to improve
CVC patency. The results of all published clinical trials are
summarized in Table 1a.19–37
Heparin catheter lock
Although heparin lock has been used for decades with
relative safety, the rate of CVC thrombosis ranges between
4.0 and 5.5 episodes/1000 days, and the rate of CVC loss due
to malfunction is 1.8–3.6/1000 days.19–21,33–35,37 The concen-
tration of heparin used as a CVC lock solution varies between
1000 and 10,000U/ml. In a prospective trial comparing a
period of high concentration (10,000U/ml) versus a period
of low-concentration (1000U/ml) heparin lock, there was no
significant difference in CVC malfunction or bleeding
complications, although the need for TPA therapy was
fourfold higher (Po0.001) with low-concentration heparin
lock.33 Theoretically, high-concentration heparin lock may be
advantageous in reducing both TPA use and TPA-related
costs; however, when Holley and Bailey34 considered the
differential cost/treatment between low- and high-concentra-
tion heparin lock ($0.20 vs $2.67), low-concentration heparin
resulted in significant savings despite higher TPA use. Low-
concentration heparin lock (1000U/ml) is particularly
advantageous in the immediate post-insertion period.38 In
a retrospective analysis comparing heparin lock (5000U/ml)
versus lower dose heparin lock (1000U/ml) or citrate
administered immediately after tunneled CVC insertion,
patients receiving the higher concentration heparin lock
(5000U/ml) had a ninefold increase in composite bleeding
events (P¼ 0.01), and 7.7% experienced a major bleeding
event (vs 0% in the low-dose heparin or citrate group).38 A
significant increase in severe hemorrhage after CVC insertion
was associated with heparin lock (5000U/ml) in a large
randomized controlled trial compared with citrate 30% lock
(severe hemorrhagic events: heparin 13% vs citrate 4%,
P¼ 0.005).24
Heparin lock has been traditionally administered as a
thrice-weekly interdialytic dwell. However, the results
of a recently published small prospective study reported
improved efficacy using a 6-day per week heparin-locking
regimen. Although this protocol is impractical in an
outpatient HD setting, it may be useful in hospitalized HD
patients with CVCs. One caveat to this protocol is that more
frequent accessioning of the CVC lumen has the potential to
increase the risk of infectious contamination, especially if
there is a break in sterile technique.39
Risks associated with heparin use
In addition to the bleeding risk, there are other potential
complications associated with heparin lock. First, the
potential for heparin contamination of blood drawn for
international neutralization rate (INR) sampling is a concern
and may lead to error in adjustment of the coumadin dose if
acted upon. One strategy for improving the accuracy of INR
testing from patients with heparin-locked CVCs is to
withdraw between 10 and 20ml of blood before obtaining
a CVC line sample. Alternatively, the INR sample can
be drawn from the arterial line before administering a
heparin bolus for dialysis.40,41 Rioux et al.42 reported a minor
overestimation of INR (mean 0.2±0.2) in patients with
Thrombus Catheter
Figure 4 |A fibrin sheath noted with contrast injected at the
time of catheter exchange. The tip of the catheter is indicated
for reference. Picture courtesy of Dr D Rajan, University of
Toronto.
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Table 1a | Studies evaluating the prevention of hemodialysis catheter malfunction: catheter-locking agents
Agent
First author,
year N
Study
design Treatment groups Outcome Effect P-value Comment
Heparin Thomas,
200733
273 P Heparin
(1000U/ml)
Heparin
(10,000U/ml)
Catheter dysfunction
(per 1000 HD
sessions)
Low H/high H
6.7 vs 7.6
NS —
Thrombolytic
therapy (per
1000 HD session)
Low H/high H
26.6 vs 8.2
o0.001
Heparin Holley, 200734 64 R Heparin
(1000U/ml)
Heparin
(10,000U/ml)
Thrombolytic
therapy (per 6
months)
Low H/high H
63 vs 31%
o0.001
Citrate (4%) Buturovic,
199819
30 RCT Citrate 4% Heparin
(1666U/ml)
Polygeline
(3.5%)
Catheter survival
(days)
C/H/P
51/23/32
o0.01 —
Citrate (4%) Lok, 200720 250 P Citrate 4% Heparin
(5000U/ml)
Thrombolytic
rate (per 1000 days)
C/H
3.3 vs 5.5
o0.001 —
Catheter removal
for poor flow
(per 1000 days)
C/H
1.65 vs 2.98
0.042
Citrate (4%) Grudzinski,
200721
307 R Citrate 4%a Heparin
(10,000U/ml)b
Thrombolytic rate
(per 1000 days)
C/H
3.23 vs 4.10
0.07 Citrate: estimated
85% reduction in
costs
Catheter removal
for poor flow
(per 1000 days)
C/H
1.88 vs 1.81
NS
Citrate (4%) MacRae,
200835
61 RCT Citrate 4% Heparin
(5000U/ml)
Thrombolytic
therapy (6 months)
C/H
41 vs 45%
NS Citrate: 36%
reduction in
bleeding events
Citrate: Estimated
80% reduction in
costs
Citrate (5%) Hendrickx,
200122
19 RCT Citrate 5% Heparin
(5000U/ml)
Thrombolytic
therapy (per HD
session)
C/H
8 vs 1%
NS —
Aspiration
of thrombus
(6 months)
C/H
14 vs 7%
o0.001
Citrate (30%) Stas, 200123 11 P Citrate 30% Heparin
(5000U/ml)
Aspiration of
thrombus
C=H NS —
Citrate (30%) Weijmer,
200524
291 RCT Citrate 30% Heparin
(5000U/ml)
Thrombolytic
therapy
(6 months)
C/H
47 vs 44%
NS Citrate: 70%
reduction in
major bleeding
events P=0.01
Catheter removal
for poor flow
(per 1000 days)
C/H
3.2 vs 3.6
NS
Citrate (47%) Bayes, 199925 10 P Citrate,
46.7%
Heparin
(5000U/ml)
Qb C=H NS —
Citrate (47%) Power, 200936 232 RCT Citrate,
46.7%
Heparin
(5000U/ml)
Thrombolytic
therapy (per 1000
days)
C/H
8.2 vs 4.3
o0.001 Citrate: increase
in adverse
symptoms
Po0.001
Tissue
plasminogen
activator
Schenk,
2000125
12 P r-TPA
(1mg/ml
interdialytic
lock)
Heparin
(1000U/ml)
Qb
ml/min
Thrombolytic
therapy (4 months)
TPA/H
237 vs 208
TPA/H
0 vs 20%
0.001
—
TPA: eightfold
increase in costs
Tissue
plasminogen
activator
Gittins, 200726 9 P r-TPA
(1mg/ml
interdialytic
lock)
Heparin
(1000U/ml)
Aspiration of
thrombus
H4rTPA:
OR 2.4
0.001 TPA: eightfold
increase in costs
Clot volume H4rTPA:
OR 1.9
o0.001
Abbreviations: HD, hemodialysis; NS, non-significant; OR, odds ratio; P, prospective cohort trial; Qb, blood flow rate; R, retrospective trial; RCT, randomized controlled trial;
r-TPA, recombinant tissue plasminogen activator.
a50% on warfarin.
b53% on warfarin.
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heparin-locked CVCs when samples were drawn from the
arterial line circuit after 1 h of dialysis, independent of
intradialytic heparin administration, provided the total
heparin dose was o100U/kg over the total treatment.
Second, there is the potential for developing heparin-
associated antiplatelet antibodies (HAAb). In the HD
population, the prevalence of HAAb (by enzyme-linked
immunosorbent assay) associated with unfractionated hepar-
in is 8.1%, and the prevalence of HAAb using a functional
assay (heparin-induced platelet aggregation) or serotonin-
release assay is 3.7%.43 The risk of HAAb-associated clinical
manifestations is unclear, and clinical sequelae may be absent
despite HAAb serologic positivity. Clinical manifestations of
HAAb have been reported in 4% of HD patients and
included thrombocytopenia, frequent thrombosis of the
extracorporeal circuit, or arteriovenous fistula.44 The associa-
tion between mortality and HAAb presence in HD patients is
controversial. In a large study of 1203 HD patients, 3.7%
were HAAb positive by functional assays (heparin-induced
platelet aggregation) and followed over a 5-year period. In
this series, the HAAb-positive patients had higher mortality
(29 vs 4%, Po0.05), and more frequent thrombotic
and hemorrhagic complications (60 vs 9%, Po0.05).45
Similar findings were reported in 9/419 HD patients with
HAAb positivity (immunoglobulin G-specific platelet factor
4-heparin complex alone or with an indeterminate serotonin-
release assay) followed for 2.5 years. In an adjusted analysis,
the risk of death was increased in patients with HAAb
(positive platelet factor 4-heparin) (hazard ratio 2.68, 95% CI
1.08–6.63, P¼ 0.03), and even higher when both HAAb assays
were present (positive platelet factor 4-heparin and seroto-
nin-release assay) (hazard ratio 6.32, 95% CI 1.68–23.7,
P¼ 0.01).46 In contrast, in 596 subjects enrolled in the
CHOICE (Choices for Healthy Outcomes In Caring for End-
stage renal disease) study, 10.3% tested HAAb positive after
6 months and were followed for 3.6 years; HAAb positivity
did not predict thrombocytopenia, cardiovascular events,
venous thromboembolism, vascular access occlusion,
or death.47
The need for alternative catheter-locking agents was
never more apparent than during the 2008 heparin recall.48
The United States Food and Drug Administration identified
the heparin contaminant to be over-sulfated chondroitin
sulfate from heparin manufactured in China. Contaminated
heparin in flush solutions, single and multidose vials, and
heparin-coated medical devices may have contributed to
246 deaths reported in patients receiving heparin from
1/2007–5/2008 compared with only 55 in the previous year
(2006), and to over 800 episodes of severe anaphylactic
reactions.48
Trisodium citrate lock
In the last decade, trisodium citrate has emerged as an
alternative to heparin as a CVC-locking solution. Seven
clinical trials reported citrate lock (4, 30, or 46.7%) to be
equivalent or superior to heparin lock (5000–10,000U/ml)
with respect to the need for TPA use and number of catheters
removed for flow problems19–21,23–25,33–35 (Table 1a). In
contrast, two studies were not as optimistic. The first was a
small study (19 catheters) comparing 5% citrate to heparin
(5000U/ml).22 The rate of thrombus aspirated from the
CVC was doubled with citrate (14 vs 7%, Po0.001); however,
the rate of thrombolytic therapy was not significantly
different (P¼non-significant). In a larger recently published
randomized control trial comparing 46.7% citrate lock
versus heparin lock (5000U/ml), the need for thrombolytic
therapy was greater in the citrate group (8.2 vs 4.3/1000 days,
Po0.001); however, there was no difference in CVC
survival.35 This was an open-labelled trial, and the volume
of CVC lock was reduced when citrate-associated side
effects were reported by the patient. This may have resulted
in an increased thrombosis rate in the citrate group.
Furthermore, 3/132 patients in the citrate group accounted
for 32% of the patients requiring thrombolytic therapy,
which conferred statistical significance to the difference
between groups.
There are advantages to citrate lock that make it a
desirable option. One is that citrate has been associated with
a lower bleeding event rate. Fewer systemic bleeding events
were found using 4% citrate lock (7 in 32 patients) versus
heparin lock (5000U/ml) (21 in 29 patients) (P¼ 0.035)35 in
tunneled CVC. Even with a higher citrate concentration
(30%), in a study of tunneled (n¼ 98) and non-tunneled
(n¼ 193) CVCs in acute and chronic renal failure patients,
citrate lock (30%) was associated with a 70% reduction in
major bleeding events compared with heparin lock (5000U/ml),
(P¼ 0.01).24 Other potential advantages of citrate lock
include a reduction in biofilm formation, avoidance of
HAAb formation, lack of interference with prothrombin
assays, and lower costs. Although potential cost savings
should be evaluated individually for dialysis facilities, an
80–85% reduction in costs was calculated using citrate in
comparison with heparin in two Canadian studies.20,21 At the
present time, 4% citrate is used in the majority of Canadian
HD units, where it is available as a prefilled syringe (5ml;
Citralok MED-XL, Montreal, Quebec, Canada). In the
United States, 4% citrate is currently available in larger
volume bags (250–500ml) requiring preparation by the HD
unit staff or pharmacy.
In a 2008 position paper by the American Society of
Diagnostic Interventional Nephrologists, the working group
recommended that either heparin lock 1000U/ml or 4%
citrate lock be used in most CVCs, and that the injected
volume not exceed the internal catheter volume.49
Risks associated with citrate lock
In contrast to 4 and 30% citrate lock, high-dose citrate lock
(46.7%) has been associated with more adverse symptoms,
those most commonly reported are metallic taste and
perioral and/or digital paresthesias. In one study using a
46.7% citrate lock, 54% of patients had adverse symptoms;
however, 34% resolved with a dose reduction.36
1222 Kidney International (2010) 78, 1218–1231
rev iew MH Mokrzycki and CE Lok: Management of CVC-related malfunction
Thrombolytic agents as catheter-locking solutions
The potential advantage of fibrinolytic agents as locking
solutions is the prevention of catheter-related infections50,51
and improved catheter patency. TPA interdialytic lock to
prevent CVC thrombosis was evaluated in two small clinical
studies. Compared with alteplase lock (1mg/ml), heparin
lock (5000U/ml) was associated with more frequent
thromboses (odds ratio 2.4, 95% CI 1.5–4.0; P¼ 0.001).
TPA lock was also associated with significantly improved
blood flow rates, lower venous pressures, and fewer
complications in a small randomized cross-over study of
TPA versus heparin lock (1000U/ml) by Shenk et al.37 There
was no difference in bleeding or infectious events between the
groups. The ‘Pre-CLOT’ (Prevention of Catheter Lumen
Occlusion with recombinant-TPA versus heparin) study is a
randomized controlled trial evaluating the efficacy of weekly
TPA lock for the prevention of HD catheter malfunction.52
Until the results of this and other large, well-designed clinical
trials are available, the routine use of TPA lock in HD
catheters is not recommended.
The optimal volume of the lock solution should be
individualized according to the patient and CVC character-
istics. All tunneled CVCs leak their locking solution to some
degree, depending on their design, even when o20% of the
CVC lock volume is instilled.53 Catheter leak begins immedi-
ately after instillation and continues over a 30min period, and
is higher in non-tunneled CVCs.54,55 The excess leakage volume
is 0.16–0.48ml witho20% CVC fill volume, and 0.99–1.43ml
with420% catheter fill volume. Catheter lock overfill by 20%
has been suggested to ensure delivery of the anticoagulant to
the CVC tip and wall, and to improve catheter patency, which
is particularly desirable in situations of recurrent thrombosis.
Overfill by 20%, however, may result in the inadvertent
systemic administration of substantial amounts of heparin, and
may be problematic in the preoperative patient or in patients
with bleeding diatheses.53,56 Undesired systemic anticoagula-
tion (increased activated partial thromboplastin time) caused
by heparin lock overfill may persist for up to 4 h.57 The average
rate of major bleeding episodes associated with heparin lock
(5000U/ml) is B2.0/1000 catheter days.24 Other serious
complications may occur with alternative lock solutions. In
2000, the Food and Drug Administration issued a warning on
the use on 46.7% citrate lock after one patient death due to
cardiac arrest that was later attributed to excessive overfilling of
the catheter.58
Oral agents for prophylaxis of catheter malfunction
The use of warfarin alone or in combination with an
antiplatelet agent has been evaluated for primary prevention
of HD catheter malfunction in two randomized controlled
trials (Table 1b). The first was a study of 85 HD patients with
their first tunneled catheters who were randomized to fixed
dose warfarin (1mg/day) or placebo.29 This study was based
on a 75% reduction in CVC thrombosis rate in cancer
patients59 using fixed mini-dose warfarin (1mg/day). How-
ever, in hemodialysis patients, mini-dose warfarin was not
associated with improvement in primary unassisted patency,
assisted CVC survival, or an increase in bleeding events. Of
note, this study found that an INR of o1.00 was associated
with significantly greater risk of CVC loss due to malfunction
(hazard ratio¼ 4.0, 95% CI 1.1–14.5; P¼ 0.04) and earlier
need for thrombolytic therapy (HR 2.8, 95% CI 1.3–6.1,
P¼ 0.009).29 The second study by Coli et al.32 included 144
newly inserted HD tunneled CVCs and compared combina-
tion therapy using low-intensity warfarin (targeted to an INR
of 1.8–2.5) and ticlodipine (250mg/day) initiated within 12 h
after CVC insertion (primary prevention) to a control group
(ticlodipine alone) who received warfarin after the first
thrombosis (secondary prevention). There was a significant
reduction in CVC thrombosis/malfunction when the com-
bined regimen of warfarin and ticlodipine was used as
primary prevention compared with secondary prevention,
(0.16 vs 1.65 thrombotic events/patient year, Po0.001),
improvement in CVC flow rates, and fewer CVC removals for
malfunction (2.4 vs 17.5%, Po0.001). It should be noted,
however, that more patients in the primary prevention group
achieved adequate anticoagulation than in the secondary
prevention group (92 vs 65%, Po0.05). Furthermore, once
thrombosis has occurred, the underlying pathogenical
processes may not be reversible with antiplatelet activity
alone. There were no bleeding events associated with the
warfarin/ticlodipine combination.
Warfarin use alone for secondary prevention was eval-
uated by Zellweger et al.30 in a small, prospective study. HD
patients considered high risk (history of previous episode of
CVC dysfunction/thrombosis) for tunneled CVC malfunc-
tion were given low-intensity warfarin (INR 1.5–2.0)
compared with low-risk CVC patients (who did not receive
warfarin). Therapeutic warfarin (with adequate anticoagula-
tion) was associated with improved malfunction-free CVC
survival at 9 months (47.1%) compared with those with
inadequate anticoagulation (8.1%), (P¼ 0.01). The effect of
non-catheter-related anticoagulant/antiplatelet use on tun-
neled CVC patency was studied by Obialo et al.31 In this
prospective study, 63 HD patients who were already receiving
chronic aspirin (n¼ 21, A, 325mg/day) or therapeutic
warfarin (n¼ 11, W, target INR 2–3) therapy for an
underlying cardiovascular indication were compared with
controls (n¼ 31, C) not taking either medication. Both
aspirin and warfarin were associated with improved primary
CVC patency at 120 days compared with controls (C) (A,
91%; W, 73%; C, 29% (Po0.001)). Gastrointestinal bleeding
rates were significantly higher in those patients on aspirin
and warfarin compared with controls (A, 24%; W, 18%; C,
0%; Po0.02); elderly patients were at highest risk of bleeding
(hazard ratio 1.14, 95% CI 1.0–1.3, P¼ 0.008).
Warfarin prophylaxis should be reserved for high-risk
patients with recurrent CVC malfunction, using a low-
intensity protocol (target INR of 1.5–2.0). The efficacy and
safety of using antiplatelet agents alone for the prevention of
tunneled HD CVC malfunction has not been adequately
studied in well-designed, appropriately powered clinical
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trials. Ideally, future areas of novel research should be
targeted on the further development of modified, thrombo-
sis-resistant tunneled catheters, or on novel-locking solu-
tions, rather than on systemic therapies. There has already
been over a decade of research into surface modification of
medical devices to enhance thromboresistance, such as
isolated heparin coating, antithrombin–heparin covalent
complex coating, coatings that enhance nitric oxide release
and heparin immobilization, as well as others.27,60–67 These
data suggest that such anticoagulant coatings protect against
platelet deposition, fibrin sheath formation, and device-
related thrombosis. However, clinical data on surface-
modified HD catheters are limited (Table 1c).27,28,65 Hepar-
in-coated catheters have not been shown to improve primary
catheter patency, cumulative catheter survival, or thrombo-
lytic therapy rates, although low-bacteremia rates have been
associated with their use.28,65
Intuitively, the design, materials, and adjunctive incor-
poration of pharmacological agents to the CVC might affect
its thrombogenicity and patency; these issues are more
thoroughly discussed elsewhere in the literature.68,69
TREATMENT OF CATHETER MALFUNCTION
Intraluminal causes of malfunction: thrombosis
Acute CVC malfunction, requiring immediate attention,
presents clinically as the inability to initiate HD due to
difficulty in aspirating blood from the ports, or as the
inability to continue HD due to a Qb less than 200ml/min.
Thrombosis is the precipitating event in 30–40% of catheter
malfunction.4 The initial approach to treatment of acute
CVC malfunction is to administer a forceful saline flush,
reposition the patient, or reverse the arterial and venous
lines. However, when lines are reversed, dialyzed blood exits
from one lumen and enters the other, bypassing the systemic
circulation, causing recirculation and reduced dialysis
adequacy. Routine line reversal is not recommended. Never-
theless, if these conservative maneuvers fail, the administra-
tion of thrombolytic agents (TLA) is required.
The TLAs evaluated in clinical trials for CVC malfunction
are urokinase, streptokinase and the recombinant tissue type-
plasminogen activators (tPAs), alteplase, reteplase, and
tenecteplase. All TLAs activate the fibrinolytic system by
cleavage of plasminogen resulting in active plasmin forma-
tion. Plasmin is the active fibrin lytic. Assembly of fibrinolytic
components (for example, plasmin) at the surface of fibrin
results in fibrin degradation. The advantage of tPA over
streptokinase and urokinase is that tPA is fibrin-specific and
tPA bound to fibrin has greater affinity for and enzymatic
activity on plasminogen.70 Alteplase is more fibrin specific
than reteplase, and has a shorter half-life (3–4min).
Tenecteplase has greater fibrin specificity and an increased
resistance to plasminogen activator inhibitor-1 compared
Table 1b | Studies evaluating the prevention of hemodialysis catheter malfunction: oral agents
Oral
agent
First author,
year
(reference) N
Study
design Treatment groups Outcome Effect P-value Comment
Warfarin
(mini-dose)
Mokrzycki,
200129
85 RCT Warfarin (1mg) Placebo Primary
catheter
patency
(at 1 year)
W/P
58 vs 48%
NS —
Assisted
catheter
patency
(at 1 year)
W/P
20 vs 18%
NS
Warfarin
(low
intensity)
Zellweger,
200530
65 P Warfarin (INR
1.5–2.0) high
risk pts
Controls
low-risk
patients
Primary
catheter
patency
(at 9 mos)
Anticoagulation
adequate vs
inadequate
47 vs 8%
0.01 —
Warfarin
(high
intensity)
Obialo, 200331 63 P Aspirin 325mg/d Warfarin
(INR 2–3)
Control Primary
catheter
patency
(no. of days)
A/W/C
114/111/68
o0.001 GI bleed
A (23%),
W (18%),
C (0%)
Catheter
survival
(at 4 months)
A/W/C
91%/73%/29%
o0.001
Warfarin
(medium
intensity)
and
ticlodipine
Coli, 200632 144 RCT Primary
prevention (PP)
Warfarin (INR
1.8–2.5)+ticlodipine
250mg/day
Secondary
prevention
(SP)
(INR 1.8–2.5)+
ticlodipine
250mg/day
Catheter
dysfunction
(1 year)
Catheter
dysfunction
(events per
patient/year)
PP/SP
12 vs 52%
PP/SP
0.16 vs 1.65
o0.01
o0.001
—
Abbreviations: GI, gastrointestinal; INR, international neutralization rate; NS, non-significant; P, prospective cohort trial; RCT: randomized controlled trial.
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with alteplase.71,72 Urokinase binds to a specific cell-bound
plasminogen and results in enhanced activation of cell-bound
plasminogen.70 Streptokinase is antigenic with repeated use,
and may be associated with allergic reactions, including
hypotension (1–20%), pyrexia±rigors (1–4%), and, rarely,
anaphylaxis (0.1%). When used for restoration of CVC
patency, the intraluminal administration of both urokinase
(5000–10,000U) and tPA (2–4mg) exert no substantial effect
on systemic fibrinogen levels, fibrin degradation product,
INR, partial thromboplastin time, or platelet count.73
There have been numerous published clinical trials
evaluating the use of various TLAs for restoration of HD
catheter patency. A comparison of these trials is problematic,
due to significant heterogeneity in the study design, inclusion
criteria (for example, acute vs chronic CVC malfunction,
minimum Qb), TLA dose, fill volume/lumen size, TLA
administration protocol, CVC type (temporary vs perma-
nent), and difference in the definitions of short- and long-
term success. Indeed, the definition of success differed among
studies of CVC malfunction and has included (1) the ability
to dialyze at the current or next HD session, (2) Qb
4200ml/min, and (3) Qb 4300ml/min for the remainder
of the current or next HD session. Although trials are
discussed in this review, two detailed systematic reviews are
available in the literature.74,75
Urokinase and strepokinase therapy
From 1987 to 1998, 14 clinical trials evaluating either
urokinase and/or streptokinase were published.18,76–85
Urokinase (5000–9000U) was used as either a CVC lock or
as a systemic infusion (250,000U).18,76,77–81 The success or
recanalization rate was between 74–100%, with the exception
of one study that reported only 14% success.67 Concerns
about the safety of streptokinase with repeated use, described
above, limit its use.
From 1999 to 2002, urokinase was unavailable to
the North American market due to a Food and Drug
Administration warning about the potential for infectious
transmission from the use of neonatal kidney cells obtained
from human urine in the manufacturing process.86 In 2002,
the Food and Drug Administration approved recombinant
urokinase for the treatment of pulmonary embolism;
however, the recombinant TPAs, alteplase, reteplase, and
tenecteplase have largely replaced urokinase for the treatment
of HD CVC malfunction.
Recombinant TPAs
From 1993 to 2010, there have been 18 clinical trials
evaluating the efficacy of tPA (alteplase, reteplase, tenecte-
plase) for thrombosis in both temporary and permanent HD
CVCs (Table 2).87–102 There are no clinical trials that compare
the three TLAs. Overall, the reported short-term success rate
was between 40 and 92%. Even in a study reporting a
relatively low- and short-term success rate (59%), defined as
a Qb of 4300ml/min, 91% of patients were able to resume
dialysis.102 However, the optimal dose and dwell duration
prescription of TLA to restore CVC patency is unclear.
The TLA protocols used for the treatment of CVC
malfunction include (1) a ‘push’ protocol, in which the
TLA is instilled into the CVC lumen, followed by 0.2–0.3ml
of normal saline pushes at 10–20min intervals (ranging
between 30 and 60min total protocol duration), and (2) a
‘locking’ protocol with a short-dwell time (p60min) after
which the TLA lock is aspirated.74 Strategies for the
management of chronically malfunctioning CVCs when Qb
rates are suboptimal in two or more consecutive sessions
(Qbo300ml/min) include (1) TLA lock using
either a short-dwell time (30–60min), (2) TLA lock with a
long-dwell period (42 h, usually the interdialytic period), or
(3) TLA infusion.
Outcomes using ‘short-dwell’ tPA protocols were reported
in seven clinical trials of tunneled CVCs (one randomized
trial,87 four prospective case series, and two retrospective
reviews91–96). The overall short-term success rate ranged
Table 1c | Studies evaluating the prevention of hemodialysis catheter malfunction: heparin-coated catheters
First author, year
(reference) N
Study
design Treatment groups Outcome Effect P-value Comment
Clark, 200927 88 R Heparin-coated
catheter (+heparin
lock 5000U/ml)
Non-coated
catheter (+heparin
lock 5000U/ml)
Primary patency
(at 3 months)
HCC/NCC
82 vs 76%
NS —
Thrombosis rate
(per 1000 days)
HCC/NCC
0.8 vs 0.4
NS
Jain, 200928 175 R Heparin-coated
catheter (+heparin
lock 5000U/ml)
Non-coated
catheter (+heparin
lock 5000U/ml)
Cumulative
catheter survival
(at 6 months)
HCC/NCC
48 vs 41%
NS HCC: 50% reduction
in bacteremia
Po0.001
Thrombolytic
therapy per
1000 days)
HCC/NCC
1.8 vs 1.8
NS
Mojibian, 201065 60 R Heparin-coated
catheter (lock solution
unknown)
No comparison 10% Removed due to poor flows
No heparin-induced thrombocytopenia
Abbreviations: HCC, heparin-coated catheter; NCC, non-coated catheter; NS, non-significant; R, retrospective trial.
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22–97%. The median time to next intervention varies
between 12.5 and 30 days. Experience using a ‘long-dwell’
tPA protocol was reported in eight prospective clinical trials,
all but two non-randomized. The tPA dwell time spanned
2–72 h among studies.87,92,97,99–101,103 Short-term success was
40–100% and the median patency after TPAwas 14–30 days in
various studies.103 Within a long-dwell protocol (33±9 h),
Hilleman et al.99 performed a dose-comparison trial using
reteplase at low doses (0.5 U/lumen) versus reteplase at high
doses (2 or 3U/lumen). High-dose reteplase was associated
with an improved short-term success rate (low dose: 84% vs
high dose: 90%) and 90-day patency rate (low dose: 42% vs
high dose: 47%). The successful outcomes of both the short
and long tPA dwells are modest at 22 and 40%, respectively,
when evaluated in a double-blind placebo design87 (Table 2).
The effect of TPA dwell time on outcomes has been
specifically compared in two published clinical trials
comparing short (30–60min) and long (48–72 h) dwell
times.92,97 There was no significant difference in CVC
patency at the next HD session or 2-week patency between
the groups. There are no published clinical trials comparing
the push protocol to either the short- or long-dwell
protocols. Using a tPA push protocol, 86% of CVCs still
functioned well89 with reported median days to next
intervention of 30 days.88,104
Catheters commonly require repeated TLA instillations for
recurrent CVC malfunction. To determine patency with
subsequent TLA doses, Little et al.101 performed a prospective
cohort study following 570 CVCs for a total of 89,216
catheter-days. One or more TLA instillations were required in
99 CVCs (34%) with a median primary patency of 135 days.
Following the first TLA administration, CVCs gained an
additional 27 days of function, and were subsequently shorter
(10–18 days) after two or more TLA dwells. This is likely due
to the presence of a fibrin sleeve, which may be more
refractory to TLA therapy and require management by either
a fibrin sleeve stripping (FSS) procedure or CVC exchange.
Extraluminal cause of malfunction
Fibrin sleeves. Fibrin sleeve disruption: Mechanical dis-
ruption of the fibrin sleeve from the CVC wall is an option
for restoring CVC patency in well-positioned, non-temporary
CVCs. Traditional techniques of FSS require a femoral vein
puncture with the fibrin sleeve disrupted using balloon
angioplasty/embolectomy, pigtail stripping, or gooseneck
snaring. The snare is pulled several times until the fibrin
sleeve is freed from the CVC wall (Figure 5). A newer internal
snare maneuver is a minimally invasive procedure that can be
used to remove partially thrombosed CVC while simulta-
neously stripping the fibrin sleeve.105
The results of nine clinical trials of FSS to restore CVC
patency are summarized in Table 3.77,106–113 Immediate
functional success associated with FSS, defined as restoration
of Qb4300ml/min, is between 79 and 98%.106,108,111
Following the initial FSS procedure, most studies observed
a 3-month primary patency of 45–60%, and a shorter
6-month patency of 28–45%.77,106,109,110,113 The median
duration of additional CVC function has ranged between
2.8 and 4.5 months in these studies. In contrast, two well-
designed randomized controlled trials showed lower primary
patency rates using FSS: 31–52% at 1-month, 35% at
1.5 months, and 0 at 4 months.111,112 Gray et al.111 revealed
that only 9% of CVCs treated with FSS remained patent
2 weeks post-procedure.107 Reasons for differences in outcome
Table 2 | Summary of clinical trials using tPA for restoration of patency in hemodialysis catheters
Medication Protocol
No. of
trials
Author, year
(reference) Short-term success Long-term success
Alteplase (1–2mg) Push 4 Meers, 199988
Spry, 2001102
Eyrich, 200289
Zachiarias, 2003104
59–92% 60% Patency at 30 days
Reteplase (0.4
units/0.4ml)
Alteplase (1–2mg)
Short dwell (30min±an additional
30min dose if needed)
6 Paulsen, 199396
Castner, 200193
O’Mara, 200391
Nguyen, 200492
Falk, 200494
Hyman, 200495
69–97% 90-Day patency=53%
(reteplase)
Median days to next event =14
days (alteplase)
Reteplase (0.5–3
units/lumen)
Alteplase
(1–2.5mg)
Long dwell (21–72 h) 7 Daeihagh, 200098
Savader, 2000103
Little, 2002101
Hilleman, 200399
Nguyen, 200492
MacRae, 200597
Hamond, 2005100
79–100% 90-Day patency=25–45%
(alteplase or reteplase)
Median days to next
event =13–27 days (alteplase)
Tenecteplase
(2mg/2ml/lumen)
Placebo
Short dwell (1 h dwell±another 1 h
dwell at next HD if needed)
Short dwell (1 h dwell±long dwell of
72 h if short dwell unsuccessful)
1 Tumlin, 2010126 22% (short dwell)
40% (long dwell)
If initial success occurred:
60% at third subsequent HD
session (short dwell)
88% at third subsequent HD
session (long dwell)
Abbreviations: HD, hemodialysis; tPA, tissue type-plasminogen activator.
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between these studies may include heterogeneity in study
design and inclusion criteria, FSS technique, and catheter
type. Complications associated with FSS are infrequent or
absent in most series. Supraventricular tachycardia occurred
during the FSS procedure in one case,107 and three cases of
septic pulmonary embolism have been reported.111–113 The
most common complication is the development of a
hematoma at the puncture site (six cases) or venous
thrombosis (two cases).106,108,110–112 There has been limited
experience with the internal snare maneuver although all
patients (n¼ 7) had a 6-week primary success rate of 100%
without complications.105
Catheter exchange (CEX) over a guidewire: CEX with a
guidewire through the pre-existing subcutaneous tunnel of a
malfunctioning CVC is the last treatment option following
failed thrombolytic therapy and FSS. The immediate
technical success of CEX is 93% and CEX has comparable
infection rates to de novo CVC insertion in non-infected
CVCs.114 A primary patency post-CEX of 51% at 3 months
and 37% at 6 months were reported by Duszak et al.114
(42 catheters). The advantage of CEX compared with de novo
CVC insertion is the preservation of the vascular access site
and lower risk of pneumothorax. Complications are
uncommon, and include hemorrhage from the tunnel and
cardiac arrhythmias.114
There are three published trials comparing FSS and CEX
in malfunctioning CVCs. The first was a randomized
controlled trial reporting the superiority of CEX compared
Table 3 | Summary of clinical trials using FSS or FSD
Author, year
(reference)
FSS
procedures (n)
Immediate
technical/functional
success
Primary patency
post-procedure
Duration of
additional catheter
function Complications
Crain, 1996106 40 100%/98% 45% at 3 months
28% at 6 months
2.8 months 1 Femoral vein thrombus
Suhoki, 199677 38 —/95% Mean patency 3 months None
Haskal, 1996107 24 92%/— 9% at 2 weeks 20 days 1 Paroxysmal supraventricular
tachycardia
Rockall, 1997108 100%/79% 4.25 months 2 Groin hematomas
Brady, 1999109 131 96%/— 56% at 3 months
46% at 6 months
None
Johnstone, 1999110 16 100%/— 40% at 6 months 4.2 months 3 Groin hematomas
1 line infection after 1 week
Gray, 2000111 28 —/89% 52% at 1 month
35% at 1.5 months
32 days 1 Innominate vein thrombus
1 bacteremia after 5 weeks
Merport, 2000112 15 97%/— 31% at 1 month
0 at 4 months
9 days 1 Groin hematoma
D’Othee, 2006113 18 100%/— 72% at 1 month
60% at 3 months
45% at 6 months
4.5 months None
Catheter
exchange±FSD
Oliver, 2007106 18 +FSD/CEX
12 FSD/CEX
— 373 days +FSD/CEX
97.5 days FSD/CEX
(P=NS)
411 days +FSD/CEX
198 days FSD/CEX
(P=NS)
+FSD/CEX :
shortness of breath (n=1)
bleeding (n=3)
redness (n=2)
swelling (n=2)
FSD/CEX: bleeding (n=1); (P=NS)
Abbreviations: CEX, catheter exchange; FSD, fibrin sheath disruption; FSS, fibrin sheath stripping; NS, non-significant.
Figure 5 |Contrast is injected to highlight the fibrin sheath as
it is being stripped away from the catheter. Picture courtesy of
Dr M Simons, University of Toronto.
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with FSS for restoring patency (1-month: CEX 71% vs FSS
31%; 4-month: CEX 27% vs FSS 0, Po0.04).112 Of note,
the post-procedure primary patency rate after FSS was
lower than previously reported and the numbers studied
were small (CEX n¼ 22, FSS n¼ 15). The second was a
retrospective study reporting equivalent patency after FSS,
CEX, and CEX with disruption of the fibrin sheath. In
contrast, the third study, a randomized controlled trial,
reported a modest improvement in Qb, urea reduction rate,
and a trend toward lower use of thrombolytic dwells when
the fibrin sleeve was disrupted by angioplasty during the CEX
procedure compared with CEX without fibrin sleeve disrup-
tion.115 This study was not adequately powered for evalua-
tion of primary patency post-procedure. Disruption of a pre-
existing fibrin sleeve at the time of CEX for dysfunctional
catheters is reasonable; however, larger randomized trials are
needed.
Extraluminal thrombus. Mural thrombi are relatively
common, typically asymptomatic and are recognized with
CVC malfunction. They are easily managed with CVC
removal and anticoagulation. In contrast, large right atrial
thrombi (LAT) are rare, but pose a serious complication. The
incidence and prevalence of LAT is unknown, largely due to
the lack of symptoms. In most reported cases, the LAT was
diagnosed by echocardiography obtained for workup
of endocarditis, or for presenting symptoms of dyspnea or
hemoptysis (pulmonary emboli or hypertension), or even
coincidentally during workup for transplantation (Figure 4). In
two studies, including a combined total of 34 HD patients
with LAT, 68–83% of patients had CVC-related bacteremia,
and the most common organisms were Staphylococcus aureus
or Staphylococcal epidermidus.116,117 LAT should be suspected
if a patient previously treated for CVC-related bacteremia
continues to have persistent fever, despite CVC removal and
adequate antibiotic therapy.118 LAT may form after a
relatively brief period of CVC insertion. In a review of 22
episodes of LAT, the mean CVC vintage was 4.5 months,
although the CVC was present for only 2–4 weeks in six
cases.116 The overall mortality is approximately 27%, and is
higher when associated with bacteremia (83%) or when left
untreated (100%).116,119 LAT is best characterized with
transesophageal echocardiography as it can detect sessile
thrombi and accurately determine the size and age of
the thrombi.120,121 Magnetic resonance imaging may also
provide useful resolution of the LAT.122 The optimal
management of patients with CVC-associated LAT is surgical
thrombectomy in low-risk surgical candidates, especially
if the LAT is 42 cm and/or is adherent to both the atrial
wall and CVC, or if there is evidence of infection or
associated atrial abnormalities.116,119,123,124 The appropriate
management of high-surgical risk patients has not been well
established. The mortality reported in medically treated
patients (anticoagulation±antibiotics) is between 23 and
33%, although in one series a period of anticoagulation for
6 months was associated with resolution of LAT in 50%
of cases.116,117,119
FUTURE AREAS OF RESEARCH
Clearly, catheter malfunction is a complex problem that
requires further research. This research should span the most
basic concepts, such as a re-examination of the definition of
catheter malfunction with supporting validation studies, to
understanding the biology of catheter malfunction, including
the pathophysiology and role of thrombus and fibrin sheath
formation and the impact of the CVC’s material, size, length,
and configuration. This will provide the necessary founda-
tion for future novel research, as has been demonstrated by
early studies of anticoagulant-coated CVCs and those of
unique design.
CONCLUSION
Catheter malfunction will continue to be a costly complica-
tion of CVC use and is primarily due to intraluminal
thrombosis and/or extraluminal fibrin sleeve encasement.
The timing of occurrence may assist in determining its
etiology but late complications can occur early and early
complications can occur late. While CVC lumen-locking
agents, oral anticoagulants, and mechanical intervention are
the foundations of prevention and management of mal-
functioning CVCs, few strategies have been tested by rigorous
well-designed and appropriately powered clinical trials. The
main challenge will be in achieving the ultimate prophylaxis
of malfunctioning CVCs by performing HD without a
catheter access.
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